Health care costs and comorbidities for patients with inclusion body myositis

References

• Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007;6:620-31
   PubMed Web of Science ®Google Scholar
• Dimachkie MM, Barohn RJ. Inclusion body myositis. Neurol Clin 2014;32:629-46
   PubMed Web of Science ®Google Scholar
• Greenberg SA. Pathogenesis and therapy of inclusion body myositis. Curr Opin Neurol 2014;25:630-9
   Web of Science ®Google Scholar
• Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011;134:3176-84
   PubMed Web of Science ®Google Scholar
• Dobloug GC, Antal EA, Sveberg L, et al. High prevalence of inclusion body myositis in Norway; a population-based clinical epidemiology study. Eur J Neurol 2015;22:672-e41
   PubMed Web of Science ®Google Scholar
• Suzuki N, Aoki M, Mori-Yoshimura M, et al. Increase in number of sporadic inclusion body myositis (sIBM) in Japan. J Neurol 2012;259:554-6
   PubMed Web of Science ®Google Scholar
• Felice KJ, North WA. Inclusion body myositis in Connecticut: observations in 35 patients during an 8-year period. Medicine (Baltimore) 2001;80:320-7
   Google Scholar
• Wilson FC, Ytterberg SR, St Sauver JL, et al. Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota. J Rheumatol 2008;35:445-7
   PubMed Web of Science ®Google Scholar
• Lefter S, Hardiman O, Ryan AM. A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland. Neurology 2017;88:304-13
   PubMed Web of Science ®Google Scholar
• Capkun G, Callan A, Tian H, et al. Burden of illness and healthcare resource use in US patients with sporadic inclusion body myositis. Muscle Nerve 2017;56:861-7
   PubMed Web of Science ®Google Scholar
• Bernatsky S, Panopalis P, Pineau CA, et al. Healthcare costs of inflammatory myopathies. J Rheumatol 2011;38:885-8
   PubMed Web of Science ®Google Scholar
• Furst DE, Amato AA, Iorga ŞR, et al. Medical costs and health-care resource use in patients with inflammatory myopathies in an insured population. Muscle Nerve 2012;46:496-505
   PubMed Web of Science ®Google Scholar
• Kanellopoulos P, Baltoyiannis C, Tzioufas AG. Primary Sjögren’s syndrome associated with inclusion body myositis. Rheumatology (Oxford) 2002;41:440-4
   PubMed Web of Science ®Google Scholar
• Greenberg SA, Pinkus JL, Amato AA, et al. Association of inclusion body myositis with T cell large granular lymphocytic leukaemia. Brain 2016;39:1348-60
   Google Scholar
• Badrising UA, Schreuder GMT, Giphart MJ, et al. Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis. Neurology 2004;63:2396-8
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Illa I. Common variable immunodeficiency and inclusion body myositis: a distinct myopathy mediated by natural killer cells. Ann Neurol 1995;37:806-10
   PubMed Web of Science ®Google Scholar
• Riggs JE, Schochet SS Jr, Gutmann L, et al. Inclusion body myositis and chronic immunethrombocytopenia. Arch Neurol 1984;41:93-5
   PubMedGoogle Scholar
• Limaye VS, Lester S, Blumbergs P, et al. Idiopathic inflammatory myositis is associated with a high incidence of hypertension and diabetes mellitus. Int J Rheum Dis 2010;13:132-7
   PubMed Web of Science ®Google Scholar
• Medicare program – general information. Centers for Medicare and Medicaid Services, 2016. Available at: https://cms.hhs.gov/MedicareGeninfo/ [Last accessed 28 October 2016]
   Google Scholar
• Huang KE, Davis SA. Using the market scan database to conduct retrospective cohort studies on dermatologic treatments and conditions: benefits and pitfalls. J Dermatol Clin Res 2013;1:1004
   Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
   PubMedGoogle Scholar
• Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203
   PubMed Web of Science ®Google Scholar
• Blough DK, Ramsey SD. Using generalized linear models to assess medical care costs. Health Serv Outcomes Res Methods 2000;1:185-202
   Google Scholar
• Phillips BA, Zilko PJ, Mastaglia FL. Prevalence of sporadic inclusion body myositis in Western Australia. Muscle Nerve 2000;23:970-2
   PubMed Web of Science ®Google Scholar
• Carruthers EC, Choi HK, Sayre EC, et al. Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study. Ann Rheum Dis 2016;75:110-16
   PubMed Web of Science ®Google Scholar
• Chung WS, Lin CL, Sung FC, et al. Increased risk of venous thromboembolism in patients with dermatomyositis/polymyositis: a nationwide cohort study. Thromb Res 2014;134:622-6
   PubMed Web of Science ®Google Scholar
• Diederichsen LP, Diederichsen AC, Simonsen JA, et al. Traditional cardiovascular risk factors and coronary artery calcification in adults with polymyositis and dermatomyositis: a Danish multicenter study. Arthritis Care Res (Hoboken) 2015;67:848-54
   PubMed Web of Science ®Google Scholar
• Rai SK, Choi HK, Sayre EC, et al. Risk of myocardial infarction and ischaemic stroke in adults with polymyositis and dermatomyositis: a general population-based study. Rheumatology (Oxford) 2016;55:461-9
   PubMed Web of Science ®Google Scholar
• Ungprasert P, Cheungpasitporn W, Wijarnpreecha K, et al. Risk of ischemic stroke in patients with polymyositis and dermatomyositis: a systematic review and meta-analysis. Rheumatol Int 2015;35:905-9
   PubMed Web of Science ®Google Scholar
• Wang H, Tang J, Chen X, et al. Lipid profiles in untreated patients with dermatomyositis. J Eur Acad Dermatol Venereol 2013;27:175-9
   PubMed Web of Science ®Google Scholar
• Wang H, Cai Y, Cai L, et al. Altered lipid levels in untreated patients with early polymyositis. PLoS One 2014;9:e89827
   PubMed Web of Science ®Google Scholar
• de Moraes MT, de Souza FH, de Barros TB, et al. Analysis of metabolic syndrome in adult dermatomyositis with a focus on cardiovascular disease. Arthritis Care Res (Hoboken) 2013;65:793-9
   PubMed Web of Science ®Google Scholar
• Rosenbohm A, Buckert D, Gerischer N, et al. Early diagnosis of cardiac involvement in idiopathic inflammatory myopathy by cardiac magnetic resonance tomography. J Neurol 2015;262:949-56
   PubMed Web of Science ®Google Scholar
• Cox FM, Delgado V, Verschuuren JJ, et al. The heart in sporadic inclusion body myositis: a study in 51 patients. J Neurol 2010;257:447-51
   PubMed Web of Science ®Google Scholar
• Ahearn J, Shields KJ, Liu CC, et al. Cardiovascular disease biomarkers across autoimmune diseases. Clin Immunol 2015;161:59-63
   PubMed Web of Science ®Google Scholar
• Sherer Y, Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2006;2:99-106
   PubMedGoogle Scholar
• Rosenbaum D, Dallongeville J, Sabouret P, Brukert E. Discontinuation of statin therapy due to muscular side effects: a survey in real life. Nutr Metabol Cardiovasc Dis 2013;23:871-5
   PubMed Web of Science ®Google Scholar
• Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011;63:713-21
   PubMed Web of Science ®Google Scholar
• Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol 2001;33:289-94
   PubMed Web of Science ®Google Scholar